secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001104659-24-071792
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Carisma grants retention options: 125K shares CEO, 85K each CFO/CSO, vesting over 2 years
--------------------------------------------------------------------------------

- CEO Steven Kelly receives option for 125,000 shares; CFO Richard Morris and CSO Michael Klichinsky each get 85,000 shares.
- Exercise price equals closing price on June 17, 2024 grant date; options vest in two equal installments on first and second anniversaries.
- Grants approved by Compensation Committee to incentivize retention during implementation of revised operating plan.
- Company intends to make additional retention grants to other employees under the same plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924071792/0001104659-24-071792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924071792/tm2417340d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer